# Oral Superoxide Dismutase (GLISODin) to Decrease Melasma Severity.

> **NCT03878433** · NA · COMPLETED · sponsor: **Centre Hospitalier Universitaire de Nice** · enrollment: 40 (actual)

## Conditions studied

- Melasma

## Interventions

- **DRUG:** Glisodin
- **OTHER:** placebo

## Key facts

- **NCT ID:** NCT03878433
- **Lead sponsor:** Centre Hospitalier Universitaire de Nice
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-04-01
- **Primary completion:** 2020-01-01
- **Final completion:** 2020-07-01
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2021-09-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03878433

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03878433, "Oral Superoxide Dismutase (GLISODin) to Decrease Melasma Severity.". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT03878433. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*